Supporting advancement of complex intranasal therapies through clinical development

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its proprietary nasal delivery system is being utilized in LTR Pharma Limited's (ASX:LTP) Phase II clinical study of SPONTAN®, an investigational intranasal spray under development for the treatment of erectile dysfunction. This milestone reflects Aptar Pharma's continued commitment to supporting intranasal drug delivery technologies and supporting the development of innovative, patient-centric therapies.